NanoCarrier has prepared study protocol of NC-6004 phase II study in combination with Keytruda® (Pembrolizumab, anti-PD-1 monoclonal antibody) for head and neck cancer. NanoCarrier submitted the study protocol as CTA (Clinical Trial Authorization) to some regulatory authorities in European countries. This study expands combination therapy potency of NC-6004 in combination with immunecheck point inhibitor. NanoCarrier and its Taiwanese partner, OEP, are preparing the study protocol submission in Taiwan followed by US and EU. In worldwide, approximately 30 study sites will participate into the study.